Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Seiji Kogure"'
Publikováno v:
Journal of Arrhythmia, Vol 35, Iss 1, Pp 121-129 (2019)
Abstract Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on edoxaban has not been performed. Our ongoing po
Externí odkaz:
https://doaj.org/article/4a97200fc4514e76a4f0afed12a46995
Autor:
Akiko Hayakawa, Hirokazu Tanabe, Kazuhiro Uchino, Takeshi Yamashita, Toru Sekine, Takuyuki Matsumoto, Masato Nakamura, Tomoko Iizuka, Chie Hasegawa, Seiji Kogure, Atsushi Takita
Publikováno v:
Journal of Cardiology. 77:186-194
Background Current guidelines recommend early termination of triple therapy and the use of direct oral anticoagulants (DOAC) for non-valvular atrial fibrillation (NVAF) patients who undergo percutaneous coronary intervention (PCI), due to safety conc
Autor:
Takanari Kitazono, Tomoko Iizuka, Ken Kozuma, Masato Nakamura, Isao Usui, Seiji Kogure, Kazuhito Shiosakai, Toru Sekine
Publikováno v:
Circulation Journal. 83:637-646
Background A unique dose of prasugrel has been approved exclusively for Japanese patients, but real-world data for prasugrel at that dose in patients with ischemic heart disease (IHD) are limited. Therefore, large-scale, real-world data are needed. M
Publikováno v:
Journal of Arrhythmia, Vol 35, Iss 1, Pp 121-129 (2019)
Journal of Arrhythmia
Journal of Arrhythmia
Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on edoxaban has not been performed. Our ongoing postmarketi
Publikováno v:
The Journal of Clinical Pharmacology. 57:1479-1490
Global trial (GT) strategy and bridging (BG) strategy are currently the main clinical development strategies of oncology drugs in Japan, but the relationship between development style and drug lag and how the bridging strategy has contributed to the